Can Donepezil Cause Urinary Retention?
Donepezil does not typically cause urinary retention; in fact, the FDA label explicitly warns that cholinomimetics like donepezil may cause bladder outflow obstruction rather than retention, though this was not observed in clinical trials. 1
Mechanism and Theoretical Risk
Donepezil is a cholinesterase inhibitor that increases acetylcholine levels, which theoretically should increase bladder contractility rather than cause retention. 1 The FDA label states: "Although not observed in clinical trials of donepezil hydrochloride, cholinomimetics may cause bladder outflow obstruction." 1 This warning reflects the drug class's potential to increase detrusor muscle activity, which could worsen symptoms in patients with pre-existing bladder outlet obstruction (such as benign prostatic hyperplasia). 1
Clinical Evidence
Urodynamic Studies Show Increased Bladder Activity
Research demonstrates that donepezil actually increases bladder contractility:
A urodynamic study in 8 Alzheimer's patients found that donepezil increased detrusor pressure from 44.9 to 54.1 cm H₂O, though bladder capacity also increased from 202 to 234 ml. 2 Only one patient developed post-void residual (40 ml), which is minimal. 2
Animal studies show donepezil produces concentration-dependent contractions of rat urinary bladder strips, not relaxation or retention. 3
Overactive Bladder is the Actual Concern
The real urological side effect of donepezil is overactive bladder (OAB), not retention:
A large Medicare study of 524,975 older adults with dementia found that 5.07% developed OAB within 6 months of starting cholinesterase inhibitors. 4
Donepezil specifically increased OAB risk by 13% compared to rivastigmine (aHR 1.13; 95% CI 1.08-1.28). 4
Case reports document urinary incontinence as an adverse effect, with 7 of 94 Japanese patients developing transient incontinence on donepezil. 5
Clinical Implications
Monitor for overactive bladder symptoms (urgency, frequency, incontinence) rather than retention when prescribing donepezil. 4 The cholinergic enhancement increases bladder contractility, making urge incontinence and detrusor overactivity the primary concerns. 2, 5
Special Caution in Men with BPH
While donepezil doesn't directly cause retention, exercise caution in elderly men with known benign prostatic hyperplasia. 1 The increased bladder contractility from donepezil combined with bladder outlet obstruction from BPH could theoretically precipitate acute urinary retention, though this remains a theoretical rather than documented clinical problem. 1
Common Side Effects to Expect
The FDA-documented adverse effects of donepezil are primarily gastrointestinal (nausea, vomiting, diarrhea) and cardiovascular (bradycardia, syncope), not urinary retention. 1 Urinary incontinence appears in post-marketing surveillance but is not listed among the common trial-documented adverse events. 1, 5